Genentech’s Divarasib Outperforms Approved KRAS G12C Inhibitors In Phase III NSCLC Trial

  1. 家
  2. 国际的
  3. 美国
  4. 奥斯汀
  5. 商业（B2B）
  6. 企业出售
  1. Posted by: [email protected]
  2. Member since: June 2026
  3. Posted:
  4. 类别: 企业出售
  5. 地区: 奥斯汀 (Astin)
  6. 发帖编号: 63684214
Genentech’s Phase III Krascendo 1 trial shows divarasib significantly improves progression-free survival over approved KRAS G12C inhibitors in advanced NSCLC patients.

Austin, Businesses For Sale, Genentech’s Divarasib Outperforms Approved KRAS G12C Inhibitors In Phase III NSCLC Trial
返回 下一个
给朋友发电子邮件

Ask AI to Review This Ad

这个广告有问题吗？


How to Avoid Scams